Population Health Research Institute
Acute Coronary Syndromes

OASIS-2 (Completed)
Organization to Asssess Strategies for Ischemic Syndromes Trial


< back


The trial tested the hypothesis that recombinant hirudin (lepirudin), a direct thrombin inhibitor, would be superior to heparin, an indirect thrombin inhibitor, in patients with acute ischaemic syndromes who were receiving aspirin. The study results suggested  that recombinant hirudin is superior to heparin in preventing cardiovascular death, myocardial infarction, and refractory angina with an acceptable safety profile in patients with unstable angina or acute myocardial infarction without ST elevation. OASIS-2 is among the first large trials that evaluated the use of a direct thrombin inhibitor in acute coronary syndromes.

Study Design: Randomized controlled parallel group design.

Intervention: Recombinant hirudin, heparin.

Length of Study: 2 years

# of Patients: 10,141

Patient Populations: Unstable angina or suspected acute myocardial infarction without ST eleveation.


Not available at this time.

Main Publications (for a full listing of publications, please visit the 'Media and Publications' section)

Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Trial Investigators.  Effects of recombinant hirudin (lepirudin) compared with heparin on preventing death, myocardial infarction, refractory angina and revascularization procedures in patients with acute myocardial ischemia without ST elevation: a randomized trial.  Lancet 1999; 353: 429-438.



Print    Email
Population Health Research Institute • Hamilton, Ontario • information@phri.ca